Gain Therapeutics, Inc.(GANX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.2M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
GANX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Gain Therapeutics, Inc. (GANX), a Healthcare sector company. GANX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.2m in revenue and is scored on the micro-cap board instead. Top institutional holders of GANX by reported 13-F value include MARSHALL WACE, LLP, Potomac Capital Management, GSA CAPITAL PARTNERS LLP, based on the most recent SEC filings. GANX trades on the Nasdaq exchange and files with the SEC under CIK 1819411. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GANX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Gain Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-4.7M
D/E Ratio
Q2 2026
0.04
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+1.2% YoYOperating Income
+8.1% YoYEPS (Diluted)
+31.5% YoYTotal Assets
+88.2% YoYTotal Debt
-8.5% YoYOp. Cash Flow
+2.2% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $55.2K -60.6% | $140.1K -15.1% | $165.0K +471.3% | $28.9K |
| Net Income | $-20.2M +1.2% | $-20.4M +8.3% | $-22.3M -26.6% | $-17.6M -26.6% | $-13.9M -288.3% | $-3.6M |
| Operating Income | $-18.7M +8.1% | $-20.4M +8.5% | $-22.3M -25.2% | $-17.8M -28.6% | $-13.8M -297.4% | $-3.5M |
| EPS (Diluted) | $-0.61 +31.5% | $-0.89 +48.0% | $-1.71 -15.5% | $-1.48 -8.0% | $-1.37 -17.0% | $-1.17 |
| Total Assets | $22.8M +88.2% | $12.1M -34.9% | $18.6M -22.8% | $24.1M -38.2% | $39.0M +305.9% | $9.6M |
| Total Debt | $501.8K -8.5% | $548.7K -20.1% | $686.6K -3.5% | $711.5K -10.8% | $798.1K +8.1% | $738.3K |
| Operating Cash Flow | $-18.5M +2.2% | $-18.9M -0.0% | $-18.9M -28.4% | $-14.7M -18.8% | $-12.4M -281.6% | $-3.2M |
| Free Cash Flow | — | $-18.9M -0.1% | $-18.9M -27.5% | $-14.8M -18.9% | $-12.5M -282.1% | $-3.3M |
Get alerted when GANX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Gain Therapeutics, Inc. including:
Top Institutional Holders of GANX
MARSHALL WACE, LLP
$3.9M1,923,546 shPotomac Capital Management, Inc.
$1.9M946,400 shGSA CAPITAL PARTNERS LLP
$1.3M632,131 shCambridge Investment Research Advisors, Inc.
$1.2M568,645 shDME Capital Management, LP
$1.1M566,130 shJONES FINANCIAL COMPANIES LLLP
$1.1M608,592 shVANGUARD CAPITAL MANAGEMENT LLC
$974.9K480,269 shGEODE CAPITAL MANAGEMENT, LLC
$921.4K453,501 shBlackRock, Inc.
$558.2K274,957 shVANGUARD FIDUCIARY TRUST CO
$470.0K231,534 sh
| Fund | Value | Shares |
|---|---|---|
| MARSHALL WACE, LLP | $3.9M | 1,923,546 |
| Potomac Capital Management, Inc. | $1.9M | 946,400 |
| GSA CAPITAL PARTNERS LLP | $1.3M | 632,131 |
| Cambridge Investment Research Advisors, Inc. | $1.2M | 568,645 |
| DME Capital Management, LP | $1.1M | 566,130 |
| JONES FINANCIAL COMPANIES LLLP | $1.1M | 608,592 |
| VANGUARD CAPITAL MANAGEMENT LLC | $974.9K | 480,269 |
| GEODE CAPITAL MANAGEMENT, LLC | $921.4K | 453,501 |
| BlackRock, Inc. | $558.2K | 274,957 |
| VANGUARD FIDUCIARY TRUST CO | $470.0K | 231,534 |
More Healthcare Companies
View all Healthcare →Put GANX on your watchlist
Track score changes the day Gain Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GANX a good stock to buy?
13F Pro's AI-powered analysis of Gain Therapeutics, Inc. (GANX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GANX are available on the GANX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. GANX is classified as a small company.
Which hedge funds own GANX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GANX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Gain Therapeutics, Inc.'s investment landscape.